A phase 3, randomized, open-label study of epacadostat plus pembrolizumab, pembrolizumab monotherapy, and the EXTREME regimen as first-line treatment for recurrent/metastatic head and neck squamous cell carcinoma (R/M SCCHN): ECHO-304/KEYNOTE-669

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 36; no. 15_suppl; p. TPS6090
Main Authors Cohen, Ezra E.W., Rischin, Danny, Pfister, David G., Vermorken, Jan Baptist, Zhao, Yufan, Gowda, Hema, Ge, Joy Yang, Jin, Fan, Harrington, Kevin J.
Format Journal Article
LanguageEnglish
Published 20.05.2018
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/JCO.2018.36.15_suppl.TPS6090